
Theravance Biopharma Investor Relations Material
Latest events

Q2 2025
Theravance Biopharma
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Theravance Biopharma Inc
Access all reports
Theravance Biopharma Inc. is a biopharmaceutical company that focuses on the discovery, development, and commercialization of respiratory and organ-selective medicines. The company's primary product is YUPELRI (revefenacin), a once-daily nebulized therapy used for the maintenance treatment of chronic obstructive pulmonary disease (COPD). Theravance Biopharma is also involved in the development of Ampreloxetine, an investigational norepinephrine reuptake inhibitor, targeting neurogenic orthostatic hypotension, and has collaborations for additional research in respiratory and immunological disorders. The company is headquartered in South San Francisco, California, and its shares are listed on the NASDAQ.
Key slides for Theravance Biopharma Inc


Q1 2025
Theravance Biopharma Inc


Q2 2025
Theravance Biopharma Inc
Latest articles
)
Verisure: Security Leader Ready for a Comeback IPO
Verisure, Europe's leading monitored alarm provider, is preparing a comeback IPO in 2025 that could be one of the year's most significant listings.
16 Sep 2025
)
Stephen J. Squeri: American Express Veteran Chairman and CEO
Stephen Squeri has spent over four decades at American Express, rising through the ranks to lead one of the world's most recognized brands.
15 Sep 2025
)
Where to? The Story of Uber
Uber's journey from rule-breaking disruptor to disciplined dual-app giant, now shaping the future of mobility, delivery, and autonomy.
5 Sep 2025
Ticker symbol
TBPH
Country
🇺🇸 United States